New drug trial targets reversing fatty liver disease damage
Disease control
Ongoing
This study is testing whether an investigational drug called HM15211 can help people with NASH, a serious form of fatty liver disease. Researchers want to see if the drug can reduce liver inflammation and scarring over 12 months of treatment. The trial involves 215 adults with a …
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC